Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is positioned for strong growth with its upcoming clinical data update for prulacabtagene leucel (prula-cel) being evaluated in lupus nephritis and systemic lupus erythematosus, which is expected at the end of this month. With significant efficacy demonstrated in Phase 1 trials, a benign safety profile, and an allogeneic nature giving it an advantage over its competitors, prula-cel has the potential to provide durable therapeutic effects for a broad range of lupus symptoms. Additionally, Adicet Bio's financials show a strong cash position that will sustain the company into the second half of 2027, giving it ample time to continue its research and development efforts. While there are risks associated with clinical trials and financing needs, the current valuation of the company does not fully reflect the potential of its leading product candidate, making it an attractive investment opportunity.

Bears say

Adicet Bio is currently projected to have a total market value of $295M, resulting in a 12-month price objective of $27 per share. However, there are significant risks that could hinder this price target, including negative clinical data, slower-than-expected development timelines, setbacks in later-stage studies, failure to obtain regulatory approvals, lower-than-projected commercial success, and the potential for medium-to-long-term equity dilution. This negative outlook is driven by concerns about the company's ability to successfully develop and commercialize its pipeline products, particularly the potential for setbacks and delays in the clinical development process. Additionally, the company's current market valuation may not accurately reflect these risks and any negative developments could lead to a decline in the stock price.

ACET has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACET has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.